Extended Data Fig. 7: T1 post-contrast (top panels) and T2/FLAIR (bottom panels) MRI images for the 8 patients with measurable disease who experienced any degree of tumor regression following CAR T cell infusion. | Nature Medicine

Extended Data Fig. 7: T1 post-contrast (top panels) and T2/FLAIR (bottom panels) MRI images for the 8 patients with measurable disease who experienced any degree of tumor regression following CAR T cell infusion.

From: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

Extended Data Fig. 7

Timepoints shown include (1) the post-operative MRI scan taken on post-operative day 1 following the surgery that was performed for maximal safe tumor resection and Ommaya reservoir placement, (2) the immediate pre-CART MRI scan taken within 1-2 days prior to CAR T cell infusion, and (3) the 1-month post-CART MRI scan. No anticancer therapies were administered between scan 1 and 2, and no anticancer therapies other than CART-EGFR-IL13Ra2 cells were administered between scan 2 and scan 3. In Patient-07, an increase in enhancing tumor on the 1-month MRI was followed by spontaneous regression on the 2-month MRI, consistent with pseudo-progression.

Back to article page